Back to top
more

Viatris (VTRS)

(Delayed Data from NSDQ)

$11.35 USD

11.35
7,895,033

-0.21 (-1.82%)

Updated Aug 6, 2024 04:00 PM ET

After-Market: $11.34 -0.01 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Viatris (VTRS) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Viatris (VTRS) closed at $13.83, marking a +0.07% move from the previous day.

Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Viatris' (VTRS) Q3 earnings might have gained from the solid performance of Viagra, Dymista, and the Thrombosis portfolio.

Earnings Preview: Viatris (VTRS) Q3 Earnings Expected to Decline

by Zacks Equity Research

Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts See a 33% Upside in Viatris (VTRS): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Viatris (VTRS) points to a 33.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Theravance (TBPH) to Cut Workforce, Hypotension Study Fails

by Zacks Equity Research

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%. Stocks falls.

Why Is Viatris (VTRS) Down 3% Since Last Earnings Report?

by Zacks Equity Research

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

J&J (JNJ) Gets FDA Nod for Twice-Yearly Schizophrenia Drug

by Zacks Equity Research

J&J (JNJ) gets FDA approval for its twice-a-year treatment option for schizophrenia patients, Invega Hafyera.

Theravance (TBPH) Suffers 2nd Study Failure in Two Months

by Zacks Equity Research

Theravance's (TBPH) mid-stage candidate, izencitinib, fails in a study evaluating it in patients with ulcerative colitis.

Company News for Aug 10, 2021

by Zacks Equity Research

Companies In The News Are: BALY, CRNC, SWAV, VTRS

Viatris (VTRS) Beats on Q2 Earnings & Sales, Raises View

by Zacks Equity Research

Viatris (VTRS) beats on Q2 earnings and sales. The company raises annual guidance.

Viatris (VTRS) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Viatris (VTRS) closed the most recent trading day at $13.92, moving +1.13% from the previous trading session.

Theravance's (TBPH) Q2 Earnings Beat, Pipeline On Track

by Zacks Equity Research

Theravance's (TBPH) loss narrows in the second quarter of 2021 while revenues decline year over year. Stock up.

Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q2 results.

Viatris (VTRS) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Viatris (VTRS) closed at $14.07 in the latest trading session, marking a -1.57% move from the prior day.

TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up

by Zacks Equity Research

TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view. It expects to settle opioid litigation in the coming year.

Theravance (TBPH) COVID-19 Therapy Fails in Mid-Stage Study

by Zacks Equity Research

Theravance's (TBPH) JAK inhibitor candidate, nezulcitinib, fails to achieve statistically significant improvement in the number of respiratory failure-free days in hospitalized COVID-19 patients with lung injury.

Here's Why Pfizer (PFE) Has Been Rallying This Year So Far

by Zacks Equity Research

Pfizer's (PFE) stock is up 5.8% this year, riding high on the success of its two-shot vaccine for COVID-19.

Viatris (VTRS) Beats on Q1 Earnings & Sales, Announces Dividend

by Zacks Equity Research

Viatris (VTRS) beats on Q1 earnings while sales surpass expectations. The company announces inaugural quarterly dividend.

Theravance (TBPH) Q1 Earnings Lag Estimates, Pipeline on Track

by Zacks Equity Research

Theravance's (TBPH) loss narrows in the first quarter of 2021 while revenues decline year over year.

Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q1 results.

Will Pfizer (PFE) Deliver a Beat This Earnings Season?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.

Tracey Ryniec headshot

Bear of the Day: Viatris (VTRS)

by Tracey Ryniec

This newly created healthcare leader disappoints on full-year guidance.

Theravance (TBPH) Q4 Earnings Top Estimates, Revenues In Line

by Zacks Equity Research

Theravance's (TBPH) loss narrows in the fourth quarter of 2020 while revenues meet the consensus estimate.

Viatris (VTRS) Declines on Lackluster Outlook, Announces Dividend

by Zacks Equity Research

Viatris (VTRS) declines after it announces outlook for 2021 and reaffirms strategic commitments.

Pfizer (PFE) Q4 Earnings Miss, Sales Beat, 2021 View Upbeat

by Zacks Equity Research

Pfizer (PFE) misses estimates for earnings while beating the same for sales. It provides an upbeat financial outlook for 2021.